Rezolute, Inc. Profile Avatar - Palmy Investing

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibod…

Biotechnology
US, Redwood City [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of RZLT's Analysis
CIK: 1509261 CUSIP: 76200L309 ISIN: US76200L3096 LEI: - UEI: -
Secondary Listings
RZLT has no secondary listings inside our databases.